Drug Profile
GNKS 356
Alternative Names: GNKS-356Latest Information Update: 18 Feb 2021
Price :
$50
*
At a glance
- Originator SBI Biotech
- Class DNA; Nucleotides
- Mechanism of Action Toll-like receptor 9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 09 Feb 2021 Discontinued - Preclinical for Psoriasis in Japan (unspecified route) before February 2021 (SBI Biotech's pipeline, February 2021)
- 09 Feb 2021 Discontinued - Preclinical for Rheumatoid arthritis in Japan (unspecified route) before February 2021 (SBI Biotech's pipeline, February 2021)
- 09 Feb 2021 Discontinued - Preclinical for Systemic lupus erythematosus in Japan (unspecified route) before February 2021 (SBI Biotech's pipeline, February 2021)